{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:41:13Z","timestamp":1792291273377,"version":"4.4.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.autrev.2017.10.013","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:37:54Z","timestamp":1517359074000},"page":"215-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials"],"prefix":"10.1016","volume":"17","author":[{"given":"Guo-min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-fei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-xiong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-long","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 9","key":"10.1016\/j.autrev.2017.10.013_bb0005","first-page":"S237","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials [J]","volume":"13","author":"Strand","year":"2007","journal-title":"Am J Manag Care"},{"issue":"23","key":"10.1016\/j.autrev.2017.10.013_bb0010","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis \u2014 NEJM [J]","volume":"365","author":"Mcinnes","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis [J]","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2017.10.013_bb0020","first-page":"2569","article-title":"Rheumatoid arthritis classification criteria [J]","volume":"62","author":"Initiative","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2017.10.013_bb0025","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.25.7.1198","article-title":"Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J]","volume":"25","author":"Athyros","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0030","first-page":"231","article-title":"Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response [J]","volume":"8","author":"Kosinski","year":"2002","journal-title":"Am J Manag Care"},{"issue":"5","key":"10.1016\/j.autrev.2017.10.013_bb0035","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges [J]","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2017.10.013_bb0040","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2165\/00003495-200161120-00012","article-title":"Atorvastatin [J]","volume":"61","author":"Malhotra","year":"2001","journal-title":"Drugs"},{"issue":"9326","key":"10.1016\/j.autrev.2017.10.013_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20\u202f536 high-risk individuals: a randomised placebocontrolled trial [J]","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.10.013_bb0050","series-title":"The Cochrane Library","article-title":"Atorvastatin for lowering lipids [M]","author":"Adams","year":"2015"},{"issue":"7","key":"10.1016\/j.autrev.2017.10.013_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors [J]","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein [J]","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.autrev.2017.10.013_bb0065","first-page":"1959","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events [J]","volume":"10","author":"Libby","year":"2001","journal-title":"Acc Curr J Rev"},{"issue":"12","key":"10.1016\/j.autrev.2017.10.013_bb0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator [J]","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.autrev.2017.10.013_bb0075","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms [J]","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"9157","key":"10.1016\/j.autrev.2017.10.013_bb0080","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(98)05917-0","article-title":"Inhibition of proinflammatory cytokine production by pravastatin [J]","volume":"353","author":"Rosenson","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.autrev.2017.10.013_bb0085","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.ATV.0000163840.63685.0c","article-title":"Statins reduce interleukin-6\u2013induced C-reactive protein in human hepatocytes [J]","volume":"25","author":"Arnaud","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.autrev.2017.10.013_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11926-005-0023-x","article-title":"Trial of atorvastatin in rheumatoid arthritis [J]","volume":"7","author":"Moreland","year":"2005","journal-title":"Curr Rheumatol Rep"},{"issue":"9426","key":"10.1016\/j.autrev.2017.10.013_bb0095","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(04)16485-4","article-title":"Statins in rheumatoid arthritis\u2014two birds with one stone? [J]","volume":"363","author":"Klareskog","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0100","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.4049\/jimmunol.170.3.1524","article-title":"A novel anti-inflammatory role for simvastatin in inflammatory arthritis [J]","volume":"170","author":"Leung","year":"2003","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10067-007-0806-8","article-title":"Statin treatment for rheumatoid arthritis: a promising novel indication [J]","volume":"27","author":"Paraskevas","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0110","first-page":"170","article-title":"Changes of inflammatory cytokines in patients with rheumatoid arthritis and intervention of atorvastatin [J]","volume":"36","author":"Yu","year":"2017","journal-title":"ECG Circ"},{"issue":"8","key":"10.1016\/j.autrev.2017.10.013_bb0115","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.19082\/2700","article-title":"Evaluation of the anti-inflammatory effects of atorvastatin on patients with rheumatoid arthritis: a randomized clinical trial [J]","volume":"8","author":"Sarabi","year":"2016","journal-title":"Electron Physician"},{"issue":"5","key":"10.1016\/j.autrev.2017.10.013_bb0120","first-page":"32","article-title":"Effect of atorvastatin on the disease activity and severity of rheumatoid arthritis: double-blind randomized controlled trial [J]","volume":"10","author":"Mowla","year":"2016","journal-title":"J Clin Diagn Res"},{"issue":"9","key":"10.1016\/j.autrev.2017.10.013_bb0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.17116\/terarkh201587972-76","article-title":"Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases [J]","volume":"87","author":"Smakotina","year":"2015","journal-title":"Ter Arkh"},{"issue":"1","key":"10.1016\/j.autrev.2017.10.013_bb0130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study [J]","volume":"73","author":"Mcinnes","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.autrev.2017.10.013_bb0135","first-page":"58","article-title":"Atorvastatin in treatment of rheumatoid arthritis [J]","volume":"44","author":"Salman","year":"2014","journal-title":"Blackwell Publ"},{"issue":"8","key":"10.1016\/j.autrev.2017.10.013_bb0140","first-page":"S30","article-title":"Role of atorvastatin on disease activity of rheumatoid arthritis patients [J]","volume":"108","author":"Singh","year":"2013","journal-title":"Blackwell Publ"},{"issue":"9","key":"10.1016\/j.autrev.2017.10.013_bb0145","first-page":"2836","article-title":"Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease [J]","volume":"12","author":"Semb","year":"2012","journal-title":"Atherosclerosis Suppl"},{"issue":"5","key":"10.1016\/j.autrev.2017.10.013_bb0150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1194\/jlr.M010876","article-title":"Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis [J]","volume":"52","author":"Tang","year":"2011","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.autrev.2017.10.013_bb0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3899\/jrheum.100582","article-title":"Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis [J]","volume":"38","author":"Elbarbary","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2017.10.013_bb0160","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/keq295","article-title":"Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial [J]","volume":"50","author":"Semb","year":"2011","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2017.10.013_bb0165","first-page":"189","article-title":"A comparative study on atorvastatin versus methotrexate in rheumatoid arthritis in a double blind placebo control trial [J]","volume":"12","author":"Sandooghi","year":"2011","journal-title":"Shiraz E Med J"},{"issue":"9","key":"10.1016\/j.autrev.2017.10.013_bb0170","first-page":"21","article-title":"The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia [J]","volume":"49","author":"Nikitina","year":"2009","journal-title":"Kardiologiia"},{"issue":"7","key":"10.1016\/j.autrev.2017.10.013_bb0175","first-page":"1459","article-title":"Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study [J]","volume":"34","author":"Charles-Schoeman","year":"2007","journal-title":"J Rheumatol"},{"issue":"9426","key":"10.1016\/j.autrev.2017.10.013_bb0180","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial [J]","volume":"363","author":"Mccarey","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.10.013_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J]","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.autrev.2017.10.013_bb0190","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials [J]","volume":"7","author":"Dersimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.autrev.2017.10.013_bb0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments [J]","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"7414","key":"10.1016\/j.autrev.2017.10.013_bb0200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses [J]","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"issue":"7109","key":"10.1016\/j.autrev.2017.10.013_bb0205","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test [J]","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.autrev.2017.10.013_bb0210","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias [J]","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.autrev.2017.10.013_bb0215","first-page":"345","article-title":"C-reactive protein and the acute phase response [J]","volume":"27","author":"Gewurz","year":"1982","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.autrev.2017.10.013_bb0220","first-page":"11","article-title":"The erythrocyte sedimentation rate: old and new clinical applications [J]","volume":"4","author":"Saadeh","year":"1998","journal-title":"Women"},{"issue":"2","key":"10.1016\/j.autrev.2017.10.013_bb0225","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/cs0790161","article-title":"Response of serum interleukin-6 in patients undergoing elective surgery of varying severity [J]","volume":"79","author":"Cruickshank","year":"1990","journal-title":"Clin Sci"},{"issue":"5","key":"10.1016\/j.autrev.2017.10.013_bb0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2362.1991.tb01398.x","article-title":"Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients[J]","volume":"21","author":"Holt","year":"1991","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"10.1016\/j.autrev.2017.10.013_bb0235","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.4049\/jimmunol.168.10.5342","article-title":"p38 mitogen-activated protein kinase is activated and linked to TNF-\u03b1 signaling in inflammatory bowel disease[J]","volume":"168","author":"Waetzig","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2017.10.013_bb0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cca.2005.12.040","article-title":"The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome [J]","volume":"368","author":"Zhou","year":"2006","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.autrev.2017.10.013_bb0245","first-page":"357","article-title":"The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value [J]","volume":"15","author":"Lewandowski","year":"2008","journal-title":"Cardiol J"},{"issue":"12","key":"10.1016\/j.autrev.2017.10.013_bb0250","article-title":"Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials [J]","volume":"36","author":"Yangchun Liu","year":"2013","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.autrev.2017.10.013_bb0255","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2125.2009.03560.x","article-title":"Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database [J]","volume":"69","author":"Lodi","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2017.10.013_bb0260","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. [J]","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2017.10.013_bb0265","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bcp.2017.06.118","article-title":"Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats [J]","volume":"142","author":"Lin","year":"2017","journal-title":"Biochem Pharmacol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218300053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T16:26:18Z","timestamp":1535127978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218300053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1568997218300053"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.10.013","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-inflammatory effects of statins on patients with rheumatoid arthritis: A systemic review and meta-analysis of 15 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}